EGFR and head and neck squamous cell carcinoma: For example, T4 immunotherapy, a CAR-T cell therapy primed to antigens for the ErbB family (EGFR, HER2-4), which is highly upregulated in HNSCC [179], was studied in a dose-escalation phase-I study for locally advanced or recurrent HNSCC.